Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diabetic Ketoacidosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Diabetic Ketoacidosis. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2008-004049-27 Sponsor Protocol Number: 2008-004049-27 Start Date*: 2009-03-18
    Sponsor Name:Karolinska Univsjukhuset
    Full Title: Vätskebehandling vid akut diabetessjukdom (Diabetes ketoacidos)
    Medical condition: Studien kommer bedrivas på akut diabetessjukdom (Diabetisk ketoacidos). Studien kommer att följa patienten från akuten till IVA tills dess att ph>7,3. Gängse praxis angående medicinsk behandling ko...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012671 Diabetic ketoacidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006191-38 Sponsor Protocol Number: 004SC06084 Start Date*: 2007-01-11
    Sponsor Name:ANGELINI
    Full Title: The effects of the association bindarit irbesartan versus irbesartan alone on albuminuria of patients with Diabetic Nephropathy. Placebo-controlled study.
    Medical condition: Patients with type II diabetes with nephropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047065 Vascular disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2010-020018-27 Sponsor Protocol Number: Dbox2008/01978 Start Date*: 2012-04-19
    Sponsor Name:Tameside Hospital NHS Foundation Trust
    Full Title: Effect of Testosterone on endothelial function and Microcirculation in Type 2 Diabetic patients with Hypoganadism.
    Medical condition: Hypogonadism and erectile dysfunction in patients with type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005848-21 Sponsor Protocol Number: M11-352 Start Date*: 2013-12-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Stud...
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) BE (Prematurely Ended) GB (Completed) IE (Completed) PT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) GR (Completed) SK (Prematurely Ended) FI (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003054-16 Sponsor Protocol Number: DDZ-BOND-2017 Start Date*: 2018-07-27
    Sponsor Name:Wörwag Pharma GmbH & co. KG
    Full Title: Randomized double-blind, placebo-controlled parallel group study over 12 months to assess the effects of treatment with benfotiamine on morphometric, neurophysiological, and clinical measures in ty...
    Medical condition: diabetic polyneuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10012685 Diabetic polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2017-002177-20 Sponsor Protocol Number: RLM-MD-02 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) LV (Prematurely Ended) HU (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) AT (Completed) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001027-11 Sponsor Protocol Number: AS07/1104-001 Start Date*: 2005-06-03
    Sponsor Name:University Hospitals Coventry and Warwickshire NHS Trust
    Full Title: Diabetes in the Very Elderly Trial
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002136-16 Sponsor Protocol Number: RLM-MD-01 Start Date*: 2019-04-02
    Sponsor Name:Allergan Ltd.
    Full Title: A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BG (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002144-33 Sponsor Protocol Number: RLM-MD-04 Start Date*: 2018-11-06
    Sponsor Name:Allergan Ltd.
    Full Title: A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10051153 Diabetic gastroparesis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Completed) FR (Completed) BE (Completed) BG (Prematurely Ended) DK (Completed) AT (Prematurely Ended) LV (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002478-23 Sponsor Protocol Number: NN304-1690 Start Date*: 2007-11-15
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 52-Week, Multinational, Multi-Centre, Open-Labelled Extension Trial of Insulin Detemir in Children and Adolescents 3-17 years with Type 1 Diabetes on a Basal- Bolus Regimen with Insulin Aspart as...
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) DK (Completed) HU (Completed) CZ (Completed) FR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-012213-22 Sponsor Protocol Number: PHX1149-PROT306 Start Date*: 2009-11-11
    Sponsor Name:Phenomix Corporation
    Full Title: A Randomized, Double-Blind, Placebo- and Sitagliptin-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Rena...
    Medical condition: Type II Diabetes Mellitus in subjects with Moderate and Severe Renal Impairment including subjects on Hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045250 Type II diabetes mellitus with renal manifestations LLT
    Population Age: Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002591-14 Sponsor Protocol Number: CTC0128 Start Date*: 2020-05-29
    Sponsor Name:Belfast Health & Social Care Trust
    Full Title: The Fenofibrate And Microvascular Events in Type 1 diabetes Eye (FAME 1 Eye): A randomised trial to evaluate the efficacy on retinopathy and safety of fenofibrate in adults with type 1 diabetes. A...
    Medical condition: To evaluate the effects of once daily oral fenofibrate compared with placebo on clinically meaningful retinopathy progression over at least 3 years in adults with Type 1 diabetes (T1D) and existing...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10012608 Diabetes mellitus insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-023198-21 Sponsor Protocol Number: STH15295 Start Date*: 2011-05-25
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: The Relative Effectiveness of Pumps Over MDI and Structured Education.
    Medical condition: Type-1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-000051-18 Sponsor Protocol Number: NN304-1689 Start Date*: 2006-12-18
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 52-Week, Multinational, Multi-Centre, Open-Labelled, Randomised, Parallel, Efficacy and Safety Comparison of Insulin Detemir and NPH Insulin in Children and Adolescents 2-16 years with Type 1 Dia...
    Medical condition: Type I Diabetes
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) CZ (Completed) DK (Completed) BG (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001317-20 Sponsor Protocol Number: IMCY-T1D-003 Start Date*: 2020-09-11
    Sponsor Name:Imcyse SA
    Full Title: A Phase Ib/IIa, randomized, double-blind placebo-controlled, multicenter adaptive design clinical trial to evaluate the immune signature of the treatment with the Imotope™ IMCY-0098 and its effect ...
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) SI (Completed) LT (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001569-17 Sponsor Protocol Number: T1DM_IAH_dapa Start Date*: 2018-08-17
    Sponsor Name:Radboud university medical center
    Full Title: Effect of the SGLT-2 inhibitor dapagliflozin on impaired awareness of hypoglycemia in type 1 diabetes
    Medical condition: Type 1 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002748-10 Sponsor Protocol Number: AD-02-013 Start Date*: 2013-12-12
    Sponsor Name:Fundación para la Investigación en Enfermedades del Aparato Digestivo
    Full Title: A double-blind, randomized, multicenter, placebo-controlled, parallel-group phase IV clinical trial to assess the efficacy of pancreatic enzyme replacement therapy (PERT) in patients with pancreati...
    Medical condition: Patients with pancreatic exocrine insufficiency (PEI) secondary to type 1 diabetes mellitus (DM)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003896-24 Sponsor Protocol Number: D169AC00001 Start Date*: 2017-01-25
    Sponsor Name:AstraZeneca AB
    Full Title: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease
    Medical condition: Chronic kidney disease (CKD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) HU (Completed) DK (Prematurely Ended) ES (Completed) DE (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005153-39 Sponsor Protocol Number: LX4211.1-310-T1DM Start Date*: 2015-04-28
    Sponsor Name:Lexicon Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients with Typ...
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) AT (Completed) ES (Completed) LT (Completed) DE (Completed) GB (Completed) HU (Completed) BE (Completed) SE (Completed) NL (Completed) PL (Completed) BG (Completed) RO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003579-38 Sponsor Protocol Number: APIDR_C_02083 Start Date*: 2007-11-13
    Sponsor Name:sanofi-aventis groupe
    Full Title: Effect of insulin glulisine compared to insulin aspart and insulin lispro when administered by Continuous Subcutaneous Insulin Infusion (CSII) on specific pump parameters in patient with Type 1 Dia...
    Medical condition: Type I Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045228 Type I diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) NL (Completed) AT (Completed) HU (Completed) IT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 21:03:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA